Literature DB >> 17483710

Extracranial relapse of an anaplastic oligodendroglioma in an adolescent: case report and review of the literature.

Carol Bruggers1, Keith White, Holly Zhou, Zhong Chen.   

Abstract

Oligodendroglioma is an uncommon childhood tumor and is more chemosensitive than other malignant glial neoplasms. Treatment involves gross total resection, and if anaplastic, radiation and chemotherapy. Distinct genetic alterations are associated with improved prognosis. We report a child with a low-grade oligodendroglioma that recurred as a high-grade oligodendroglioma and ultimately as extraneural systemic relapse. It was initially responsive to temozolomide, cyclophosphamide, etoposide, and carboplatin, perhaps predicted by combined loss of heterozygosity at 1p and 19q. This chemotherapy may be promising in treating malignant oligodendroglioma. However, he succumbed to progressive systemic disease. Positron emission spectroscopy scan was useful in sequentially assessing his disease.

Entities:  

Mesh:

Year:  2007        PMID: 17483710     DOI: 10.1097/MPH.0b013e318054756e

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients.

Authors:  Fausto J Rodriguez; Tarik Tihan; Doris Lin; William McDonald; Janice Nigro; Burt Feuerstein; Sadhana Jackson; Kenneth Cohen; Peter C Burger
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

Review 2.  Occipital anaplastic oligodendroglioma with multiple organ metastases after a short clinical course: a case report and literature review.

Authors:  Gang Li; Zhiguo Zhang; Jianghong Zhang; Tianbo Jin; Hongjuan Liang; Li Gong; Guangbin Cui; Haixia Yang; Shiming He; Yongsheng Zhang; Guodong Gao
Journal:  Diagn Pathol       Date:  2014-01-21       Impact factor: 2.644

3.  Osteosclerosis Secondary to Metastatic Oligodendroglioma.

Authors:  Patrick R Maloney; Vitor Nagai Yamaki; Ravi Kumar; Derek Johnson; Christopher Hunt; Mark E Jentoft; Michelle Clarke
Journal:  Rare Tumors       Date:  2017-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.